v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Condensed Consolidated Statements Of Operations    
Sales $ 1,620,192 $ 1,692,545
Cost of sales 1,283,814 1,317,923
Gross profit 336,378 374,622
Operating expenses    
Salaries and related expenses 440,279 513,689
Selling, general and administrative 446,619 531,390
Total operating expenses 886,898 1,045,079
Loss from continuing operations (550,520) (670,457)
Other expenses    
Interest expense, net 159,217 279,386
Gain on extinguishment of debt (213,433)   
Loss on change in fair value of forward contract liability    62,214
Gain on change in fair market value of derivative (62,042)   
(Gain) or loss on change in fair value of warrant liability (324,306) 108,964
Total other expenses and income (440,564) 450,564
Net loss from continuing operations before income tax (109,956) (1,121,021)
Income taxes expense 5,355 4,198
Net loss from continuing operations, net of tax (115,311) (1,125,219)
Discontinued operations:    
Loss from operations of discontinued pharmacies, net of tax benefit (9,945) (7,795)
Net loss (125,256) (1,133,014)
Milestone feature on preferred stock (662,057)   
Net loss applicable to common stock $ (787,313) $ (1,133,014)
Net loss to common stockholders from continuing operations $ (0.07) $ (0.23)
Loss from discontinued operations, net of tax expense (benefit) $ 0.00 $ 0.00
Net loss per common share - basic and diluted $ (0.07) $ (0.23)
Basic and diluted weighted average number of common shares outstanding 11,325,668 4,901,040